PropertyValue
?:abstract
  • Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection COVID-19 is an ongoing global health crisis Efficacious drugs against COVID-19 are not yet available Therefore, rapid discovery of safe and efficacious agents against SARS-CoV-2 are needed urgently Nucleoside analogs have an integral role in the treatment of viral infections Owing to their broad-spectrum antiviral activities, C-nucleoside analogs have become key components of COVID-19 treatment regimens Here, we review the state-of-the-art C-nucleoside GS-5734 (remdesivir) that is in preclinical research for COVID-19 treatment As a potentially approved drug by the FDA against SARS-Cov-2 infection, the efficacy and safety of GS-5734 have been documented repeatedlyin vitro, in animal models, and in humans To better understand the drug-development process, this review focused on the discovery process, preparation methods, broad-spectrum activities, and antiviral mechanism of GS-5734
is ?:annotates of
?:creator
?:journal
  • New_Journal_of_Chemistry
?:license
  • unk
?:publication_isRelatedTo_Disease
is ?:relation_isRelatedTo_publication of
?:source
  • WHO
?:title
  • GS-5734: a potentially approved drug by FDA against SARS-Cov-2
?:type
?:who_covidence_id
  • #709381
?:year
  • 2020

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/d5qshg8m>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/d5qshg8m>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all